CCR Focus Archive 2012
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Oncogenic Metabolism: Cause or Consequence? (October 15, 2012)
Scientific and Regulatory Challenges in the Development of Molecular Diagnostics (March 15, 2012)
Pancreatic Cancer—Applied Science—The Assault Begins (August 15, 2012)
AACR Clinical and Translational Cancer Research Think Tank Reports (February 1, 2012)
Genetically InFormed Therapies for Children with Cancer (May 15, 2012)
Drug Development: What Experience Has Taught Us (January 1, 2012)
2012 CCR Focus Sections
Oncogenic Metabolism: Cause or Consequence?
October 15, 2012
Guest Editor: Beverly Teicher, 18 (20) : 5515–5829
Reinventing Cancer Cell Metabolism
Susan E. Bates
Targeting Cancer Metabolism
Beverly A. Teicher, W. Marston Linehan, and Lee J. Helman
c-Myc and Cancer Metabolism
Donald M. Miller, Shelia D. Thomas, Ashraful Islam, David Muench, and Kara Sedoris
Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells
Mayumi Tamada, Makoto Suematsu, and Hideyuki Saya
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Hui Yang, Dan Ye, Kun-Liang Guan, and Yue Xiong
Predicting Drug Targets and Biomarkers of Cancer via Genome-Scale Metabolic Modeling
Livnat Jerby and Eytan Ruppin
Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy
Tineke W.H. Meijer, Johannes H.A.M. Kaanders, Paul N. Span, and Johan Bussink
Pancreatic Cancer—Applied Science—The Assault Begins
August 15, 2012
Guest Editors: Manuel Hidalgo and Daniel D. Von Hoff, 18 (16) : 4217–4475
Pancreatic Cancer: Steps in the Right Direction
Susan E. Bates
Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
Manuel Hidalgo and Daniel D. Von Hoff
Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing
Christine A. Iacobuzio-Donahue Victor E. Velculescu, Christopher L. Wolfgang, and Ralph H. Hruban
The Pancreas Cancer Microenvironment
Christine Feig, Aarthi Gopinathan, Albrecht Neesse, Derek S. Chan, Natalie Cook, and David A. Tuveson
Heterogeneity and Targeting of Pancreatic Cancer Stem Cells
Vesselin R. Penchev, Zeshaan A. Rasheed, Anirban Maitra, and William Matsui
Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
Anne Le, N.V. Rajeshkumar, Anirban Maitra, and Chi V. Dang
Genetically InFormed Therapies for Children with Cancer
May 15, 2012
Guest Editors: Carol J. Thiele and Susan L. Cohn, 18 (10) : 2733–2800
Progress in Pediatric Cancer
Susan E. Bates
Genetically InFormed Therapies — A "GIFT" for Children with Cancer
Carol J. Thiele and Susan L. Cohn
Promising Therapeutic Targets in Neuroblastoma
Katherine K. Matthay, Rani E. George, and Alice L. Yu
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp
Using Germline Genomics to Individualize Pediatric Cancer Treatments
Navin Pinto, Susan L. Cohn, and M. Eileen Dolan
Scientific and Regulatory Challenges in the Development of Molecular Diagnostics
March 15, 2012
Guest Editor: J. Milburn Jessup and Stephen M. Hewitt, 18 (6) : 1513–1562
Molecular Diagnostics: Are We There Yet?
Susan E. Bates
Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development
George Poste, David P. Carbone, David R. Parkinson, Jaap Verweij,
Stephen M. Hewitt, and J. Milburn Jessup
Impact of Preanalytic Factors in the Design and Application of Integral Biomarkers for Directing Patient Therapy
Stephen M. Hewitt, Sunil S. Badve, and Laurence D. True
Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use
P. Michael Williams, Tracy G. Lively, J. Milburn Jessup, and Barbara A. Conley
Development and Use of Integral Assays in Clinical Trials
Richard L. Schilsky, James H. Doroshow, Michael LeBlanc, and Barbara A. Conley
Lessons Learned from the Investigational Device Exemption (IDE) Review of Children's Oncology Group Trial AAML1031
Soheil Meshinchi, Stephen P. Hunger, Richard Aplenc, Peter C. Adamson, and J. Milburn Jessup
Biomarker Discovery, Development, and Implementation in France: A Report from the French NCI and Cooperative Groups
Fabrice Andre, Frederique Nowak, Monica Arnedos, Ludovic Lacroix, Patrice Viens, and Fabien Calvo
AACR Clinical and Translational Cancer Research Think Tank Reports
February 1, 2012
Guest Editors: Kenneth C. Anderson and Raymond N. DuBois, 18 (3) : 606–644
A Millennium Goal for Cancer
Susan E. Bates
Overview of the AACR Clinical and Translational Cancer Research Think Tank Meeting
Kenneth C. Anderson and Raymond N. DuBois
Impact of Genomics on Personalized Cancer Medicine
Carlos L. Arteaga and José Baselga
Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics
David R. Parkinson, Bruce E. Johnson, and George W. Sledge
Genetically Modified Mouse Models for Biomarker Discovery and Preclinical Drug Testing
Raju Kucherlapati
Imaging: Strategies, Controversies, and Opportunities
Ronald Blasberg and David Piwnica-Worms
Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials
Donald A. Berry, Roy S. Herbst, and Eric H. Rubin
Drug Development: What Experience Has Taught Us
January 1, 2012
Guest Editors: Giuseppe Giaccone and Susan E. Bates, 18 (1) : 21–76
On Drug Development, Chance, and the Prepared Mind
Susan E. Bates
Drug Development: Portals of Discovery
Susan E. Bates, Laleh Amiri-Kordestani, and Giuseppe Giaccone
BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
Alexander Marzuka Alcalá and Keith T. Flaherty
The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
Michael Pollak
Inhibitors Targeting Mitosis: Tales of How Great Drugs Against a Promising Target Were Brought Down by a Flawed Rationale
Edina Komlodi-Pasztor, Dan L. Sackett, and Antonio Tito Fojo
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Len Neckers and Paul Workman